DoubleLine ETF Adviser’s Synopsys SNPS Stock Holding History

DoubleLine ETF Adviser’s Portfolio SNPS Stock Details SNPS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,143	Closed	-$441K	–	242
2023 Q1	$441K	Buy	1,143 +182	+19%	+$65K	0.19%	113
2022 Q4	$307K	Buy	+961	New	+$301K	0.16%	142

Other funds holding SNPS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

DoubleLine ETF Adviser's SNPS Position: Q2 2023 in Review

DoubleLine ETF Adviser sold out of Synopsys (SNPS) in Q2 2023, closing a stake of 1,143 shares — an estimated $441K sold.

DoubleLine ETF Adviser first reported a position in SNPS in Q4 2022 and held it in 2 quarters. The position peaked at $441K in Q1 2023. 1,014 funds tracked by Wall St. Rank hold SNPS as of Q2 2023.

DoubleLine ETF Adviser reported no remaining Synopsys position as of Q2 2023 after selling out during the quarter.
DoubleLine ETF Adviser sold 1,143 Synopsys shares in Q2 2023, an estimated $441K.
DoubleLine ETF Adviser first reported a position in Synopsys in Q4 2022 and held it in 2 quarters.
DoubleLine ETF Adviser's Synopsys position peaked at $441K in Q1 2023.
1,014 funds tracked by Wall St. Rank held Synopsys as of Q2 2023.

Based on DoubleLine ETF Adviser's 13F filing for Q2 2023, filed 14 Aug 2023.